|
|
|
European Biopharmaceutical Review
|
Drug development is an arduous process punctuated by go/no-go decisions related to the efficacy and safety of drug candidates. When a new preclinical drug candidate with a reasonable profile of efficacy and safety is identified, it is still uncertain whether this new therapeutic agent will ultimately make its way to the patient and advance human health. In fact, ~90% of all compounds entering clinical trials fail, largely due to safety issues in clinical phases or drug efficacy issues in patients (1).
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
Judi Wardwell is a Senior Application Scientist at InSphero, with more than 25 years of experience working in the pharma industry. Prior to joining InSphero, she was the Manager of a functional genomic group at Bristol-Myers Squibb, where she developed physiologically relevant cell models and conducted phenotypic screens to identify new drug targets in developing integrated approaches to target identification. Judi has also held scientific research positions at Wyeth and Hoffmann-La Roche.
Dr Radina Kostadinova is Lead Product Manager for InSphero 3D InSight™ Liver Toxicology and Disease Platforms. She has more than 17 years of research experience in industry and academic settings, working in the fields of molecular and cellular biology and preclinical mechanistic toxicology. At InSphero, her focus is to develop and establish liver tissue models for detection of drug toxicity, as well as 3D liver disease models for the study of fibrosis, inflammation, diabetes, and obesity.
Professor Armin Wolf is Chief Scientific Officer at InSphero and Professor of Toxicology at the Technical University of Kaiserslautern, Germany. An accomplished pharma R&D executive and board-certified toxicologist with more than 30 years’ cumulative experience at Janssen and Novartis, Armin offers a first-hand perspective on the challenges facing the pharma industry and the need for more physiologically relevant human models to improve efficiency in drug discovery and safety testing.
|
|
|
Judi Wardwell |
|
|
|
|
Judi Wardwell |
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
SGD Pharma takes lead in sustainability, awarded Platinum EcoVadis rating for the first time
Puteaux Cedex, FRANCE – XX January: SGD Pharma, a leading
supplier of glass primary packaging in the pharmaceutical industry, has
been awarded a ‘platinum’ rating by EcoVadis, positioning it in the top
1% of all companies rated worldwide. This highlights SGD Pharma’s
commitment to sustainable practices and corporate social responsibility
(CSR).
EcoVadis is the internationally
recognized sustainability ratings provider, evaluating over 75,000
companies globally across a range of different industries.
More info >> |
|
 |
White Papers |
 |
|
Quality By Design
Biopharma Group
Quality by Design (QbD) is a systematic approach to development that begins with the defined objectives and emphasizes science and quality risk management in order to achieve those goals. QbD ensures that the quality of the product is built into production processes from the outset, rather than being tested after development has already commenced.
More info >> |
|
 |
Industry Events |
 |
Pharma Integrates 2021
16 November 2021, VIRTUAL CONFERENCE
Now in its tenth year, Pharma Integrates is a unique event bringing
together pharma and healthcare leaders across the Pharmaceutical
pipeline to address their needs, to share insights and create debate on
crucial topics that influence the future of patient outcomes.
More info >> |
|
|
.jpg)
